CClinicalTrials.gg
WithdrawnNCT03959813PSYCHOMOTPALUpdated Sep 20, 2021

Evaluation of the Impact of Psychomotricity on the Patients Body Experience in Palliative Care

An observational study in Palliative Care, sponsored by University Hospital, Strasbourg, France. Withdrawn. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-09-20.

Sponsored by University Hospital, Strasbourg, France · Observational

Why this study was withdrawn
the ethics committee has not accepted the extension
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
0
Ages
18 Years and older
Sex
All
01

Study summary

Palliative care is part of a comprehensive approach to the person, in the advanced phase of a serious illness. The purpose of this care is to relieve painful symptoms, to promote comfort and quality of life. In the context of a serious illness, the sick person is confronted with body modifications that have an impact on his body experience, that is, on his feelings and on the image that he has of his body.

Psychomotricity is a paramedical discipline that focuses on body-psyche links. The psychomotor therapist is authorized to take care of psychomotor disorders, as defined in the decree of competences. These psychomotor disorders appear in connection with the evolution of the serious illness and the presence of symptoms in these patients (ex: disorders of the tonic regulation, psychomotor disharmony, disorders of the representation of the body, etc.). In palliative care, the psychomotor therapist seeks to regulate these psychomotor disorders and thus to promote a more satisfying physical experience in the patient, through the use of different bodily approaches.

Several studies have shown the beneficial effects of touching and moving the body in cancer patients, but no work evaluating the effects of the psychomotor approach (involving various body mediations) on the body experience of patients with cancer in palliative situation

02

Conditions studied

  • Palliative Care
03

In context

Lead sponsor

University Hospital, Strasbourg, France is the lead sponsor of 966 studies on the registry; 342 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

patients hospitalized in palliative care units

Inclusion criteria

  • Age greater than or equal to 18 years
  • Man or woman
  • Subject who has agreed to participate in the research and to use the data collected for research purposes
  • Patient with solid cancer or hematological malignancy in palliative stage, that is to say a cancerous disease for which no curative treatment is no longer envisaged, with committed vital prognosis
  • Hospitalize patient in palliative care unit
  • Patient with indication of care in psychomotricity defined by the decree of competence Decree n ° 88-659 of May 6, 1988
  • Patient with a minimum score of 4 on an item or a minimum score of 4 on several cumulative items (with a minimum of 2 on at least one of the items), on the ESAS scale, among the following themes: pain, anxiety, depression, uneasy feeling

Exclusion criteria

Exclusion Criteria:

  • Patient whose clinical condition (left to the decision of the investigator) does not allow to perform a psychomotor care and / or participate in a recorded interview (extreme fatigue, confusion, painful uncontrolled symptoms)
  • Communication difficulties, patient not speaking or not understanding French
  • Impossibility of giving the patient informed information (subject in emergency situation, difficulties in understanding the subject, etc.)
  • Patient under guardianship, curatorship
  • Patient not affiliated to social welfare regime
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
0 participants (actual)
Patient registry
No

Interventions

  • OtherPsychomotricity by touching and passive mobilizations

    The patient will have a first psychomotricity session. It will be carried out remotely from the drug catches to avoid bias induced by their administration having effects on the symptoms studied. Before and after the session, two evaluations will be offered to the patient and performed by a nurse: * A questionnaire, based on the physical experience, * The ESAS scale will be administered to the patient to assess the importance of symptoms (pain, depression, anxiety, discomfort) During the session, a touch treatment will be offered to promote awareness of the body. Passive mobilizations at the level of the members and the axis will then be proposed, to promote the pleasure of being in motion. A touch treatment will be done again to promote relaxation. A questionnaire can be offered to the patient after 4 sessions to assess his perception of psychomotricity.

06

What researchers measure

Primary outcomes

  1. Realization of a questionnaire, based on the patient's global and physical feeling

    questionnaire used to assess the impact of psychomotor care on the body experience of patients with advanced palliative care cancer, in both a physical and psychological dimension

    Time frame: 30 minutes before psychomotor care

  2. Realization of a questionnaire, based on the patient's global and physical feeling

    questionnaire used to assess the impact of psychomotor care on the body experience of patients with advanced palliative care cancer, in both a physical and psychological dimension

    Time frame: 30 minutes after psychomotor care

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 20, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03959813
Lead sponsor
University Hospital, Strasbourg, France
Responsible party
Sponsor
First posted
May 22, 2019
Start date
Sep 1, 2019
Primary completion
Jul 1, 2021
Completion
Jul 1, 2021
Last update
Sep 20, 2021

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Sep 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion